Optimizing the Design and Analysis of Clinical Trials for Antibacterials against Multidrug-resistant Organisms: A white paper from Combacte's STaT-net

Clinical Infectious Diseases

Volumn 67, Issue 12, 2018, Pages 1922-1931

  De Kraker, Marlieke E A ^a   Sommer, Harriet ^b   De Velde, Femke ^c   Gravestock, Isaac ^d   Weiss, Emmanuel ^e,f   McAleenan, Alexandra ^g   Nikolakopoulos, Stavros ^h   Amit, Ohad ⁱ   Ashton, Teri ⁱ   Beyersmann, Jan ^j   Held, Leonhard ^d   Lovering, Andrew M ^k   MacGowan, Alasdair P ^k   Mouton, Johan W ^c   Timsit, Jean François ^l,m   Wilson, David ⁿ   Wolkewitz, Martin ^b   Bettiol, Esther ^a   Dane, Aaron ^o   Harbarth, Stephan ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f BEAUJON HOSPITAL   (France)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ GLAXOSMITHKLINE   (United States)

^j UNIVERSITY OF ULM   (Germany)

^k SOUTHMEAD HOSPITAL   (United Kingdom)

^l UNIVERSITÉ PARIS DIDEROT   (France)

^m BICHAT HOSPITAL   (France)

ⁿ ASTRAZENECA   (United Kingdom)

^o DaneStat Consulting Limited   (United Kingdom)

more..

Author keywords

Antibacterial drug development; Clinical trial design; Multidrug resistant organisms; Novel biostatistical methods; Randomized clinical trials

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BAYESIAN LEARNING; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG DESIGN; DRUG MEGADOSE; DRUG SENSITIVITY; EVIDENCE BASED PRACTICE; HUMAN; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTIDRUG RESISTANCE; OPTIMAL DRUG DOSE; PATIENT; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRAGMATIC TRIAL; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW (TOPIC); TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; BAYES THEOREM; EVIDENCE BASED MEDICINE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BAYES THEOREM; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85057551975     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy516     Document Type: Article

References (48)

1. Bush K, Page MGP. What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. J Pharmacokinet Pharmacodyn 2017; 44:1-20.
2. Bettiol E, Wetherington JD, Schmitt N, Harbarth S; COMBACTE consortium. Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals. Antimicrob Agents Chemother 2015; 59:3695-9.
3. Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 2012; 55:1031-46.
4. European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. EMA/CHMP/351889/2013. 2013. Available at: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf. Accessed 22 October 2017.
5. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. 2013. Available at: www.fda.gov/downloads/Drugs/Guidances/UCM359184.pdf. Accessed 22 October 2017.
6. Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrug-resistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis 2017; 65:141-6.
7. Rex JH, Goldberger M, Eisenstein BI, Harney C. The evolution of the regulatory framework for antibacterial agents. Ann N Y Acad Sci 2014; 1323:11-21.
8. Kostyanev T, Bonten MJ, O'Brien S, et al. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother 2016; 71:290-5.
9. Innovative Medicines Initiative. 6th Call for proposals. 2012. Available at: https://ec.europa.eu/research/participants/portal4/doc/call/fp7/imi-ju-06-2012/32291-call_topic_imi_ju_2012_6th_call_for_proposals_en.pdf. Accessed 3 July 2018.
10. de Velde F, de Winter BC, Koch BC, van Gelder T, Mouton JW; COMBACTE-NET consortium. Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. J Antimicrob Chemother 2016; 71:2909-17.
11. Gravestock I, Held L. Power priors based on multiple historical studies for binary outcomes. arXiv.org. 2017. Available at: https://arxiv.org/abs/1708.08239 v3. Accessed 3 July 2018.
12. Gravestock I, Held L; COMBACTE-Net consortium. Adaptive power priors with empirical Bayes for clinical trials. Pharm Stat 2017; 16:349-60.
13. Sommer H, Bluhmki T, Beyersmann J, et al; COMBACTE-NET. Assessing non-inferiority in treatment trials regarding severe infectious diseases: an extension to the entire follow-up period using a cure-death multistate model. Antimicrob Agents Chemother 2018; 62:e01691-17.
14. Sommer H, Timsit JF, Wolkewitz M; COMBACTE-NET consortium. Bezlotoxumab and recurrent Clostridium difficile infection. N Engl J Med 2017; 376:1594.
15. Sommer H, Wolkewitz M, Schumacher M; COMBACTE-NET consortium. The time-dependent “cure-death” model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogens. Pharm Stat 2017; 16:267-79.
16. Timsit JF, de Kraker MEA, Sommer H, et al; COMBACTE-NET consortium. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net. Intensive Care Med 2017; 43:1002-12.
17. Weiss E, Essaied W, Adrie C, Zahar JR, Timsit JF. Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials. Crit Care 2017; 21:162.
18. McAleenan A, Higgins J, MacGowan A, Hope W, Mouton JW. Systematic review of clinical PK-PD studies of antibacterials. 2015. Workshop on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2015/09/event_detail_001223.jsp&mid=WC-0b01ac058004d5c3. Accessed 10 November 2017.
19. De Velde F, De Winter BCM, Koch BCP, Van Gelder T, Mouton JW. Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis. J Antimicrob Chemother 2018; 73:469-76.
20. Muller AE, Theuretzbacher U, Mouton JW. Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. Clin Microbiol Infect 2015; 21:881-5.
21. European Medicines Agency. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. 2016. Available at: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500210982.pdf. Accessed 10 November 2017.
22. Food and Drug Administration. Complicated urinary tract infections: developing drugs for treament. Guidance for Industry. 2015. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070981.pdf. Accessed 10 November 2017.
23. de Grooth HJ, Parienti JJ, Oudemans-van Straaten HM. Should we rely on trials with disease- rather than patient-oriented endpoints? Intensive Care Med 2018; 44:464-6.
24. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33:176-82.
25. Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis 2015; 61:800-6.
26. van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163-71.
27. Schweitzer VA, van Smeden M, Postma DF, Oosterheert JJ, Bonten MJM, van Werkhoven CH. Response adjusted for days of antibiotic risk (RADAR): evaluation of a novel method to compare strategies to optimize antibiotic use. Clin Microbiol Infect 2017; 23:980-5.
28. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment. 2014. Available at: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm234907.pdf. Accessed 10 November 2017.
29. Beyersmann J, Di Termini S, Pauly M. Weak convergence of the wild bootstrap for the Aalen-Johansen estimator of the cumulative incidence function of a competing risk. Scand J Stat 2013; 40:387-402.
30. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997; 16:901-10.
31. Huque MF, Valappil T, Soon GG. Hierarchical nested trial design (HNTD) for demonstrating treatment efficacy of new antibacterial drugs in patient populations with emerging bacterial resistance. Stat Med 2014; 33:4321-36.
32. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials 2010; 7:5-18.
33. Schmidli H, Gsteiger S, Roychoudhury S, O'Hagan A, Spiegelhalter D, Neuenschwander B. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics 2014; 70:1023-32.
34. Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382:1705-13.
35. Hueber W, Sands BE, Lewitzky S, et al; Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61:1693-700.
36. Hobbs BP, Carlin BP, Sargent DJ. Adaptive adjustment of the randomization ratio using historical control data. Clin Trials 2013; 10:430-40.
37. President's Council of Advisors on Science and Technology (PCAST). Report to the president on combating antibiotic resistance. 2014. Available at: www.broadinstitute.org/files/sections/about/PCAST/2014%20pcast-amr.pdf. Accessed 24 January 2018.
38. Viele K, Berry S, Neuenschwander B, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat 2014; 13:41-54.
39. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015; 313:1619-20.
40. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377:62-70.
41. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016; 375:65-74.
42. Ventz S, Barry WT, Parmigiani G, Trippa L. Bayesian response-adaptive designs for basket trials. Biometrics 2017; 73:905-15.
43. McDonnell A, Rex JH, Goossens H, Bonten M, Fowler VG Jr, Dane A. Efficient delivery of investigational antibacterial agents via sustainable clinical trial networks. Clin Infect Dis 2016; 63(suppl 2):S57-9.
44. Powers JH, Evans SR, Kesselheim AS. Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits? BMJ 2018; 360:k587.
45. Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models with R. New York, NY: Springer, 2011.
46. Allignol A, Schumacher M, Wanner C, Drechsler C, Beyersmann J. Understanding competing risks: a simulation point of view. BMC Med Res Methodol 2011; 11:86.
47. Dane A, Wetherington JD. Statistical considerations associated with a comprehensive regulatory framework to address the unmet need for new antibacterial therapies. Pharm Stat 2014; 13:222-8.
48. Ruberg SJ. Making what's advanced today routine tomorrow. J Biopharm Stat 2016; 26:55-70.